, Volume 173, Issue 3–4, pp 434–439 | Cite as

Chronic MDMA (ecstasy) use, cognition and mood

  • K. McCardle
  • S. Luebbers
  • J. D. Carter
  • R. J. Croft
  • C. StoughEmail author
Original Investigation



It has been suggested that 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) causes damage to the serotonergic system, and that this damage results in cognitive and mood impairments.


To examine the effect of chronic MDMA usage on a wide battery of cognitive tests and psychological abilities and processes.


In the present study, the performance of 17 participants with a history of MDMA use was compared to the performance of 15 control subjects on a battery of neuropsychological tests. This battery included tests for depression, immediate word recall, delayed recall, attention and working memory.


Results indicated that the MDMA group had significantly higher scores for depression than the control group, and displayed poorer delayed recall and verbal learning than controls after accounting statistically for the effects of cannabis and depression.


These results suggest that MDMA users exhibit difficulties in coding information into long-term memory, display impaired verbal learning, are more easily distracted, and are less efficient at focusing attention on complex tasks.


Ecstasy Cognition Mood MDMA 


  1. Altman HJ, Nordy DA, Ogren SO (1984) Role of serotonin in memory: facilitation by alaproclate and zimeldine. Psychopharmacology 84:496–502PubMedGoogle Scholar
  2. Baddeley A, Emslie H, Nimmo-Smith I (1992) Speed and capacity of language processing test manual. UK Thames Valley Test Company, Bury St Edmunds, UKGoogle Scholar
  3. Beck A, Steer R, Ball R, Ranieri W (1996) Comparison of Beck Depression Inventories-IA and -II in psychiatric outpatients. J Person Assess 67:588–597Google Scholar
  4. Bolla KI, McCann UD, Ricaurte GA (1998) Memory impairment in abstinent MDMA (“MDMA”) users. Neurology 51:1532–1537PubMedGoogle Scholar
  5. Cole J, Sumnall H, Grob C (2002) Sorted: ecstasy facts and fiction. Psychologist 15:464–467Google Scholar
  6. Croft RJ (2002) “Danger” remains best message. Psychologist 15:470–471Google Scholar
  7. Croft RJ, Klugman A, Baldeweg T, Gruzelier JH (2001a) Electrophysiological evidence of serotonergic impairment in long-term MDMA (“ecstasy”) users. Am J Psychiatry 158:1687–1692PubMedGoogle Scholar
  8. Croft RJ, Mackay A, Mills A, Gruzelier JH (2001b) The relative contributions of ecstasy and cannabis to cognitive impairment. Psychopharmacology 153:373–379CrossRefPubMedGoogle Scholar
  9. Curran HV, Travill RA (1997) Mood and cognitive effects of ±3,4-methylenedioxymethamphetamine (MDMA): weekend “high” followed by mid-week low. Addiction 92:821–831CrossRefPubMedGoogle Scholar
  10. Downing J (1986) The psychological physiological effects of MDMA on normal volunteers. J Psychoact Drugs 18:335–339Google Scholar
  11. Giovagnoli AR, Del Pesce M, Mascheroni S, Simonceli M, Laiacona M, Captitani E (1996) Trail making test: normative values from 287 normal adult controls. Ital J Neurol Sci 17:305–309PubMedGoogle Scholar
  12. Gouzoulis-Mayfrank E, Daumann J, Tuchtenhagen F, Pelz S, Becker S, Kunert H, Fimm B, Sass H (2000) Impaired cognitive performance in drug free users of recreational ecstasy (MDMA). J Neurol Neurosurg Psychiatry 68:719–725PubMedGoogle Scholar
  13. Grob CS (2000) Deconstructing MDMA: the politics of MDMA research. Addict Res 8:549–588Google Scholar
  14. Harold K (2001) The pharmacology and toxicology of “ecstasy” (MDMA) and related drugs. Can Med Assoc J 165:917–928Google Scholar
  15. Kish SJ (2002) How strong is the evidence that brain serotonin neurons are damaged in human users of ecstasy? Pharmacol Biochem Behav 71:845–855Google Scholar
  16. Krystal JH, Price LH, Opsahl C, Ricaurte GA, Heninger GR (1992) Chronic 3,4-methylenedioxymetamphetamine (MDMA) use: effects on mood and neuropsychological function? Am J Drug Alcohol Abuse 18:331–341PubMedGoogle Scholar
  17. Lezak MD (1995) Neuropsychological assessment, 3rd edn. Oxford University Press, New YorkGoogle Scholar
  18. McEntee WJ, Crook TH (1991) Serotonin, memory, and the aging brain. Psychopharmacology 103:143–149PubMedGoogle Scholar
  19. McCann UD, Szabo Z, Scheffel U, Dannals RF, Ricaurte GA (1998) Positron emission tomographic evidence of toxic effect of MDMA (“ecstasy”) on brain serotonin neurons in human beings. Lancet 352:1433–1437PubMedGoogle Scholar
  20. McCann UD, Mertl M, Eligulashvili V, Ricaurte GA (1999) Cognitive performance in (±)3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”) users: a controlled study. Psychopharmacology 143:417–425PubMedGoogle Scholar
  21. McNair DM, Lorr M, Droppleman LF (1992) Manual for the Profile of Mood States. Educational and Industrial Testing Service, San Diego, Calif.Google Scholar
  22. Molliver ME, Berger UV, Mamounas LA, Molliver DC, O’Hearn E, Wilson MA (1990) Neurotoxicity of MDMA and related compounds: anatomic studies. Ann N Y Acad Sci 600:640–664Google Scholar
  23. Morgan MJ (1999) Memory deficits associated with recreational use of “ecstasy” (MDMA). Psychopharmacology 141:30–36CrossRefPubMedGoogle Scholar
  24. Parrott AC (2002) Very real, very damaging. Psychologist 15:472–473Google Scholar
  25. Parrott AC, Lasky J (1998) Ecstasy (MDMA) effects upon mood and cognition: before, during and after a Saturday night dance. Psychopharmacology 139:261–268CrossRefPubMedGoogle Scholar
  26. Peroutka SJ, Newman H, Harris H (1988) Subjective effects of 3,4-methylenedioxymethamphetamine in recreational users. Neuropsychopharmacology 1:273–277PubMedGoogle Scholar
  27. Reneman L, Lavalaye J, Schmand B, de Wolff FA, van den Brink W, den Heeten GJ, Booij J (2001) Cortical serotonin transporter density and verbal memory in individuals who stopped using 3,4-methylenedioxymethamphetamine (MDMA or “ecstasy”). Arch Gen Psychiatry 58:901–906PubMedGoogle Scholar
  28. Rey A (1964) L’examen clinique psychologie. Presses Universitaires de France, ParisGoogle Scholar
  29. Ricaurte GA, Martello AL, Katz JL, Martello MB. (1992) Lasting effects of (±)3,4-methylenedioxymethamphetamine on central serotonergic neurons in non-human primates. J Pharmacol Exp Theory 261:616–622Google Scholar
  30. Schear JM, Sato SD (1989) Effects of visual acuity and visual motor speed and dexterity on cognitive test performance. Arch Clin Neuropsychol 4:25–32CrossRefPubMedGoogle Scholar
  31. Schifano F (2000) Potential human neurotoxicity of MDMA (“ecstasy”): subjective self-reports, evidence from an Italian drug addiction centre and clinical case studies. Neuropsychobiology 42:25–33PubMedGoogle Scholar
  32. Semple DM, Ebmeier KP, Glabus MF, O’Carroll RE, Johnstone EC (1999) Reduced in vivo binding to the serotonin transporter in the cerebral cortex of MDMA (“ecstasy”) users. Br J Psychiatry 175:63–69PubMedGoogle Scholar
  33. Solowij N, Hall W, Lee N (1992) Recreational MDMA use in Sydney: a profile of “ecstasy” users and their experiences with the drug. Br J Addict 87:1161–1172PubMedGoogle Scholar
  34. Steele T, McCann UD, Ricaurte GA (1994) 3,4-Methylendioxymethamphetamine (“ecstasy”): pharmacology and toxicology in animals and humans. Addiction 89:539–551PubMedGoogle Scholar
  35. Wechsler D (1981) WAIS-R manual. Psychological Corporation, New YorkGoogle Scholar
  36. Wood SJ, Proffitt T, Mahony K, Smith DJ, Buchanan JA, Brewer W, Stuart GW, Velakoulis D, McGorry PD, Pantelis C (2002) Visuospatial memory and learning in first-episode schizophreniform psychosis and established schizophrenia: a functional correlate of hippocampal pathology? Psychol Med 32:429–438CrossRefPubMedGoogle Scholar
  37. Young SN, Smith SE, Pihl RO, Ervin FR (1985) Tryptophan depletion causes a rapid lowering of mood in normal males. Psychopharmacology 87:173–177PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  • K. McCardle
    • 1
  • S. Luebbers
    • 1
  • J. D. Carter
    • 1
  • R. J. Croft
    • 1
  • C. Stough
    • 1
    Email author
  1. 1.Swinburne Centre for NeuropsychologySwinburne UniversityHawthornAustralia

Personalised recommendations